CD86 and colorectal carcinoma: Our analysis implicated candidate proteins that have been reported evidence with CRC in either gene polymorphisms, mRNA levels, or protein levels from previous genetic or experiment studies, including GREM1, CHRDL2, CSF2RA, CD86, CXADR, MMP2, and TIMP2, among which three (GREM1, CSF2RA, CD86) were prioritized with the most convincing evidence (tier 1).